Cargando…

The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke

OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Goebel, Silvia, Li, Zhongmin, Vogelmann, Jasmin, Holthoff, Hans-Peter, Degen, Heidrun, Hermann, Dirk M., Gawaz, Meinrad, Ungerer, Martin, Münch, Götz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720811/
https://www.ncbi.nlm.nih.gov/pubmed/23935828
http://dx.doi.org/10.1371/journal.pone.0066960
_version_ 1782277994305290240
author Goebel, Silvia
Li, Zhongmin
Vogelmann, Jasmin
Holthoff, Hans-Peter
Degen, Heidrun
Hermann, Dirk M.
Gawaz, Meinrad
Ungerer, Martin
Münch, Götz
author_facet Goebel, Silvia
Li, Zhongmin
Vogelmann, Jasmin
Holthoff, Hans-Peter
Degen, Heidrun
Hermann, Dirk M.
Gawaz, Meinrad
Ungerer, Martin
Münch, Götz
author_sort Goebel, Silvia
collection PubMed
description OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myocardial infarction or ischemic stroke with potent anti-ischemic effects have been developed, but all incur a significant risk of bleeding. METHODS: Platelet adhesion and thrombus formation after endothelial injury was monitored in the carotid artery by intra-vital fluorescence microscopy. The morphological and clinical consequences of stroke were investigated in a mouse model with a one hour-occlusion of the middle cerebral artery. RESULTS: Thrombus formation was significantly decreased after endothelial injury by 1 mg/kg Revacept IV, compared to Fc only. 1 mg/kg Revacept IV applied in mice with ischemic stroke immediately before reperfusion significantly improved functional outcome, cerebral infarct size and edema compared to Fc only. Also treatment with 10 mg/kg rtPA was effective, and functional outcome was similar in both treatment groups. The combination of Revacept with rtPA leads to increased reperfusion compared to treatment with either agent alone. In contrast to rtPA, however, there were no signs of increased intracranial bleeding with Revacept. Both rtPA and Revacept improved survival after stroke compared to placebo treatment. Revacept and vWF bind to collagen and Revacept competitively prevented the binding of vWF to collagen. CONCLUSIONS: Revacept reduces arterial thrombus formation, reduces cerebral infarct size and edema after ischemic stroke, improves functional and prognostic outcome without intracranial bleeding. Revacept not only prevents GPVI-mediated, but probably also vWF-mediated platelet adhesion and aggregate formation. Therefore Revacept might be a potent and safe tool to treat ischemic complications of stroke.
format Online
Article
Text
id pubmed-3720811
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37208112013-08-09 The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke Goebel, Silvia Li, Zhongmin Vogelmann, Jasmin Holthoff, Hans-Peter Degen, Heidrun Hermann, Dirk M. Gawaz, Meinrad Ungerer, Martin Münch, Götz PLoS One Research Article OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Several antiplatelet drugs for the treatment of myocardial infarction or ischemic stroke with potent anti-ischemic effects have been developed, but all incur a significant risk of bleeding. METHODS: Platelet adhesion and thrombus formation after endothelial injury was monitored in the carotid artery by intra-vital fluorescence microscopy. The morphological and clinical consequences of stroke were investigated in a mouse model with a one hour-occlusion of the middle cerebral artery. RESULTS: Thrombus formation was significantly decreased after endothelial injury by 1 mg/kg Revacept IV, compared to Fc only. 1 mg/kg Revacept IV applied in mice with ischemic stroke immediately before reperfusion significantly improved functional outcome, cerebral infarct size and edema compared to Fc only. Also treatment with 10 mg/kg rtPA was effective, and functional outcome was similar in both treatment groups. The combination of Revacept with rtPA leads to increased reperfusion compared to treatment with either agent alone. In contrast to rtPA, however, there were no signs of increased intracranial bleeding with Revacept. Both rtPA and Revacept improved survival after stroke compared to placebo treatment. Revacept and vWF bind to collagen and Revacept competitively prevented the binding of vWF to collagen. CONCLUSIONS: Revacept reduces arterial thrombus formation, reduces cerebral infarct size and edema after ischemic stroke, improves functional and prognostic outcome without intracranial bleeding. Revacept not only prevents GPVI-mediated, but probably also vWF-mediated platelet adhesion and aggregate formation. Therefore Revacept might be a potent and safe tool to treat ischemic complications of stroke. Public Library of Science 2013-07-23 /pmc/articles/PMC3720811/ /pubmed/23935828 http://dx.doi.org/10.1371/journal.pone.0066960 Text en © 2013 Goebel et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Goebel, Silvia
Li, Zhongmin
Vogelmann, Jasmin
Holthoff, Hans-Peter
Degen, Heidrun
Hermann, Dirk M.
Gawaz, Meinrad
Ungerer, Martin
Münch, Götz
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title_full The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title_fullStr The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title_full_unstemmed The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title_short The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
title_sort gpvi-fc fusion protein revacept improves cerebral infarct volume and functional outcome in stroke
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720811/
https://www.ncbi.nlm.nih.gov/pubmed/23935828
http://dx.doi.org/10.1371/journal.pone.0066960
work_keys_str_mv AT goebelsilvia thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT lizhongmin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT vogelmannjasmin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT holthoffhanspeter thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT degenheidrun thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT hermanndirkm thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT gawazmeinrad thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT ungerermartin thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT munchgotz thegpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT goebelsilvia gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT lizhongmin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT vogelmannjasmin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT holthoffhanspeter gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT degenheidrun gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT hermanndirkm gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT gawazmeinrad gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT ungerermartin gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke
AT munchgotz gpvifcfusionproteinrevaceptimprovescerebralinfarctvolumeandfunctionaloutcomeinstroke